NCT07163260Enrolling by invitation
Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia
Source: ClinicalTrials.gov · Last updated 24 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study will help to better understand the course of disease in people with haemophilia (A or B \[with or without inhibitors\]) and the haemophilia care scenario in the selected countries and the experience so far in dealing with the condition. This is a survey-based study; hence no medications or other treatments will be provided to participants as a part of this study.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 244 (estimated)
- First submitted
- 6 Aug 2025
- Start date
- 31 Jan 2025
- Primary completion date
- 19 Dec 2025
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Haemophilia
- NCT number
- NCT07163260
What you commit to
- Study type: Observational
- Planned participants: 244
- From 31 Jan 2025 to the primary completion date, 19 Dec 2025
- 4 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There is no explicit exclusion criterion in this study, thus any participants group who answers "no" to any of the inclusion criteria will be excluded from the study.
Who the study is looking for
- For Experienced/Senior Treating Physicians
- Experienced/senior haematologist treating haemophilia (adult or paediatric) or physician treating patients with haemophilia. (PWH), with greater than 5 years of experience.
- Able to communicate in English or country specific language.
- Agree/sign informed consent before data collection. For Patients Organisations
- Patient organisation supporting haemophilia.
- Expert having greater than 3 years of work experience with the patient organisation.
- Expert level understanding of haemophilia landscape and care pathway in the relevant country.
- Able to communicate in English or country specific language.
- Agree/sign informed consent before data collection. For Patients/Caregivers
- Patients of all age groups, diagnosed with haemophilia A or haemophilia B (with or without inhibitors) for greater than 2 years.
- For patients less than 18 years of age (\*less than 19 years for South Korea), their caregivers aged greater than or equal to 18 years (\*greater than or equal to19 years for South Korea) should sign the informed consent.
- \*For South Korea, the adult age is 19 years.
- Able to communicate in English or country specific language.
- Agree/sign informed consent before data collection.
Sex: All
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Bangalore | India | Unknown status |
| - Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| - Coordinator of this site? Confirm its status | Kuala Lumpur | Malaysia | Unknown status |
| - Coordinator of this site? Confirm its status | Bangkok | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.